464 Studies Now Enrolling
A Phase III, Double-Blind, Randomised Study to Assess the Efficacy and Safety ofAZD9291 versus a Standard of Care Epidermal Growth Factor Receptor TyrosineKinase Inhibitor as First-Line Treatment in Patients with Epidermal Growth FactorReceptor Mutation Positive, Locally Advanced or Metastatic Non-Small Cell LungCancer
A study for patients with non-small cell lung cancer using study drug AZD9291
| Sponsor: | AstraZeneca |
| Enrolling: | Male and Female Patients |
| IRB Number: | AAAO4614 |
| U.S. Govt. ID: | NCT02296125 |
| Contact: | Joan Zimmeck: 000-000-0000 / jcz2106@cumc.columbia.edu |
Additional Study Information:
The FLAURA Study is a new clinical research study underway in NSCLC and we are looking for people who would like to join. This study will examine an investigational drug, called AZD9291, and compare it tostandard, approved drugs that are already used to treat lung cancer. These drugs are called gefitinib and erlotinib. When we talk about investigational, it means that a drug has not yet been approved for clinical use and is still being evaluated in clinical studies like this one. The purpose of the FLAURA Study is to see if AZD9291 is better than the standard treatment at extending the time before your lung cancergets worse.
This study is closed
